181 related articles for article (PubMed ID: 8319521)
21. Improved blood glucose control by insulin therapy in type 2 diabetic patients has no effect on lipoprotein(a) levels.
Wolffenbuttel BH; Leurs PB; Sels JP; Rondas-Colbers GJ; Menheere PP; Nieuwenhuijzen Kruseman AC
Diabet Med; 1993 Jun; 10(5):427-30. PubMed ID: 8334821
[TBL] [Abstract][Full Text] [Related]
22. Relationships of C-peptide levels and the C-peptide/bloodsugar ratio with clinical/biochemical variables associated with insulin resistance in orally-treated, well-controlled type 2 diabetic patients.
Relimpio F; Losada F; Pumar A; García de Pesquera F; Morales F; Acosta D; Astorga R
Diabetes Res Clin Pract; 1997 Jun; 36(3):173-80. PubMed ID: 9237784
[TBL] [Abstract][Full Text] [Related]
23. Serum lipoprotein(a) is increased in hypertensive NIDDM patients.
Hancu N; Netea MG; Iancu S
Diabetes Care; 1995 Jun; 18(6):879-80. PubMed ID: 7555518
[No Abstract] [Full Text] [Related]
24. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
Fulcher GR; Catalano C; Walker M; Farrer M; Thow J; Whately-Smith CR; Alberti KG
Diabet Med; 1992 Dec; 9(10):908-14. PubMed ID: 1478035
[TBL] [Abstract][Full Text] [Related]
25. Effects of insulin on cholesterol synthesis in type II diabetes patients.
Scoppola A; Testa G; Frontoni S; Maddaloni E; Gambardella S; Menzinger G; Lala A
Diabetes Care; 1995 Oct; 18(10):1362-9. PubMed ID: 8721938
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics of type II diabetic subjects consuming high versus low carbohydrate diets in Mexico City and San Antonio, Texas.
Gonzélez C; Stern MP; Mitchell BD; Valdez RA; Haffner SM; Pérez BA
Diabetes Care; 1994 May; 17(5):397-404. PubMed ID: 8062606
[TBL] [Abstract][Full Text] [Related]
27. Impact of intensified dietary therapy on energy and nutrient intakes and fatty acid composition of serum lipids in patients with recently diagnosed non-insulin-dependent diabetes mellitus.
Laitinen JH; Ahola IE; Sarkkinen ES; Winberg RL; Harmaakorpi-Iivonen PA; Uusitupa MI
J Am Diet Assoc; 1993 Mar; 93(3):276-83. PubMed ID: 8382712
[TBL] [Abstract][Full Text] [Related]
28. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.
Hollander PA; Elbein SC; Hirsch IB; Kelley D; McGill J; Taylor T; Weiss SR; Crockett SE; Kaplan RA; Comstock J; Lucas CP; Lodewick PA; Canovatchel W; Chung J; Hauptman J
Diabetes Care; 1998 Aug; 21(8):1288-94. PubMed ID: 9702435
[TBL] [Abstract][Full Text] [Related]
29. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM.
Cummings MH; Watts GF; Umpleby AM; Hennessy TR; Naoumova R; Slavin BM; Thompson GR; Sönksen PH
Diabetologia; 1995 Aug; 38(8):959-67. PubMed ID: 7589883
[TBL] [Abstract][Full Text] [Related]
30. Effects of a monounsaturated fatty acid-enriched hypocaloric diet on cardiovascular risk factors in obese patients with type 2 diabetes.
Gumbiner B; Low CC; Reaven PD
Diabetes Care; 1998 Jan; 21(1):9-15. PubMed ID: 9538963
[TBL] [Abstract][Full Text] [Related]
31. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up.
Clauson P; Karlander S; Steen L; Efendic S
Diabet Med; 1996 May; 13(5):471-7. PubMed ID: 8737030
[TBL] [Abstract][Full Text] [Related]
32. Serum lipids and lipoprotein(a) concentrations in Chinese NIDDM patients. Relation to metabolic control.
Chang CJ; Kao JT; Wu TJ; Lu FH; Tai TY
Diabetes Care; 1995 Aug; 18(8):1191-4. PubMed ID: 7587858
[TBL] [Abstract][Full Text] [Related]
33. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus.
Ak G; Buyukberber S; Sevinc A; Turk HM; Ates M; Sari R; Savli H; Cigli A
J Diabetes Complications; 2001; 15(3):150-7. PubMed ID: 11358684
[TBL] [Abstract][Full Text] [Related]
34. Metabolic effects and clinical value of beet fiber treatment in NIDDM patients.
Karlander S; Armyr I; Efendic S
Diabetes Res Clin Pract; 1991 Feb; 11(2):65-71. PubMed ID: 1850691
[TBL] [Abstract][Full Text] [Related]
35. Islet cell antibodies at diagnosis, but not leanness, relate to a better cardiovascular risk factor profile 5 years after diagnosis of NIDDM.
Gottsäter A; Ahmed M; Lilja B; Fernlund P; Sundkvist G
Diabetes Care; 1996 Jan; 19(1):60-3. PubMed ID: 8720536
[TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy and tolerability of pravastatin in hypercholesterolemia in patients with non-insulin-dependent diabetes mellitus. Hyogo Pravastatin Study Group.
Kazumi T; Yoshino G; Ishida Y; Iwatani I; Morita S; Tateiwa M; Kasuga M
Diabetes Res Clin Pract; 1995 Jan; 27(1):61-8. PubMed ID: 7781495
[TBL] [Abstract][Full Text] [Related]
37. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
Nauck MA; Weber I; Bach I; Richter S; Orskov C; Holst JJ; Schmiegel W
Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
[TBL] [Abstract][Full Text] [Related]
38. Plasma lipoproteins and apolipoproteins in insulin-dependent and young non-insulin-dependent Arab women.
al-Muhtaseb N; al-Yuosuf AR; Bajaj JS
Acta Diabetol Lat; 1991; 28(1):61-9. PubMed ID: 1862693
[TBL] [Abstract][Full Text] [Related]
39. Lipoproteins and apolipoproteins in young nonobese Arab women with NIDDM treated with insulin.
Al-Muhtaseb N; Al-Yusuf AR; Abdella N; Fenech F
Diabetes Care; 1989 May; 12(5):325-31. PubMed ID: 2656141
[TBL] [Abstract][Full Text] [Related]
40. Metabolic effects of dietary fructose in diabetic subjects.
Bantle JP; Swanson JE; Thomas W; Laine DC
Diabetes Care; 1992 Nov; 15(11):1468-76. PubMed ID: 1468273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
